Clinical Trials Logo
  1. Home
  2. Severe Asthma
  3. NCT03629782

Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy — RECOGNISE  

Severe Asthma Clinical Trial

Official title:
Characterisation of Patients With Severe Asthma in Primary and Secondary Care Settings in Europe Reported to be Eligible for Biological Therapy

Clinical Trial Summary

This is a multi-country, multicentre, observational cross-sectional one-visit study of patients suffering from severe asthma in primary and secondary care settings in Europe

Clinical Trial Description

This study aims to generate real-world data on the characteristics of patients considered to have severe asthma in primary and secondary care settings that should be referred for assessment for biologics. It is anticipated that these data from European countries, will help to estimate the unmet need for better treatments in severe asthma patients and will provide supporting evidence on the current shortcomings in referrals to asthma specialist or secondary care clinics. This information could also support the development of better severe asthma care pathways across Europe. Approximately 1,500 other patients like you will take part in the RECOGNISE study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03629782
Study type Observational
Source AstraZeneca
Contact
Status Completed
Phase
Start date April 26, 2018
Completion date July 31, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05018299 - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma Phase 2
Recruiting NCT05472324 - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma. Phase 2
Recruiting NCT04914078 - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed NCT05576454 - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects Phase 1
Recruiting NCT04520165 - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting NCT04438408 - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting NCT04463836 - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Enrolling by invitation NCT06421402 - K-HEALTH in AIR - Barcelona Pilot - Cohort
Recruiting NCT03377920 - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's. N/A
Recruiting NCT04565483 - Predictive Signature of Benralizumab Response Phase 4
Recruiting NCT04045587 - International Severe Asthma Registry: Canadian Cohort
Completed NCT05616338 - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC) N/A
Active, not recruiting NCT02038374 - Clinico-biological Correlation of Severe Asthma in Children N/A
Active, not recruiting NCT02114034 - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting NCT06035289 - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting NCT03532685 - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up N/A
Completed NCT03931954 - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting NCT03984253 - Swiss Severe Asthma Register
Recruiting NCT03435237 - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting NCT03476109 - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Phase 4